A
Alcista
Alcista · 25%MGRX
$1.71
Precio del escenario
$0.200
+0.009 (+4.28%)Al cierre
Loading chart…
- Máximo
- 0.209
- Apertura
- 0.192
- Precio medio ponderado por volumen
- 0.20
- Volumen
- 319.40K
- Capitalización
- 9.35M
- Mínimo
- 0.186
- Importe
- 63.39K
- EV/EBITDA, TTM
- 0.00
Mangoceuticals, Inc. is focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx and is also focused on wellness solutions. It is advancing its proprietary antiviral compound MGX-0024. The Company offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. It has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin.
Análisis de IA of Mangoceuticals Inc (MGRX)
VenderMangoceuticals Inc is not a good buy right now due to its extremely low RSI of 18.24, indicating oversold conditions, and a staggering year-to-date change of -76.56%.
Métricas de valoración
El PER previsto actual de Mangoceuticals Inc (MGRX) es 0.00, frente a su media de 5 años de 0.00.
Escenarios de precio de Alphio AI para MGRX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
8.510-09NewsfilterMangoceuticals Closes $2.5 Million Investment Deal
8.508-07GlobenewswireMangoceuticals Prices Public Offering, Raising $1.2 Million
- 8.503-06Newsfilter
Mangoceuticals Files for Global Patent Protection on Antiviral Additive
8.502-20BenzingaMangoceuticals Stock Surges 42.12% Amid TRT Sales Growth
- 4.502-20Benzinga
U.S. Stocks Rise, Nasdaq Gains Over 200 Points
Preguntas frecuentes sobre MGRX, respondidas por Alphio AI
Mangoceuticals, Inc. is focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx and is also focused on wellness solutions. It is advancing its proprietary antiviral compound MGX-0024. The Company offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. It has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).
Mangoceuticals Inc is not a good buy right now due to its extremely low RSI of 18.24, indicating oversold conditions, and a staggering year-to-date change of -76.56%.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.